{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T09:01:34Z","timestamp":1780736494265,"version":"3.54.1"},"reference-count":52,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FOC"],"published-print":{"date-parts":[[2013,2]]},"abstract":"\n Object<\/jats:title>\n The authors' goal was to review the current understanding of the underlying molecular and genetic mechanisms involved in low-grade glioma development and how these mechanisms can be targets for detection and treatment of the disease and its recurrence.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n On October 4, 2012, the authors convened a meeting of researchers and clinicians across a variety of pertinent medical specialties to review the state of current knowledge on molecular genetic mechanisms of low-grade gliomas and to identify areas for further research and drug development.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The meeting consisted of 3 scientific sessions ranging from neuropathology of\n IDH1<\/jats:italic>\n mutations;\n CIC<\/jats:italic>\n ,\n ATRX<\/jats:italic>\n , and\n FUBP1<\/jats:italic>\n mutations in oligodendrogliomas and astrocytomas; and\n IDH1<\/jats:italic>\n mutations as therapeutic targets. Sessions consisted of a total of 10 talks by international leaders in low-grade glioma research, mutant\n IDH1<\/jats:italic>\n biology and its application in glioma research, and treatment.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The recent discovery of recurrent gene mutations in low-grade glioma has increased the understanding of the molecular mechanisms involved in a host of biological activities related to low-grade gliomas. Understanding the role these genetic alterations play in brain cancer initiation and progression will help lead to the development of novel treatment modalities than can be personalized to each patient, thereby helping transform this now often-fatal malignancy into a chronic or even curable disease.<\/jats:p>\n <\/jats:sec>","DOI":"10.3171\/2012.12.focus12349","type":"journal-article","created":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T13:36:20Z","timestamp":1359725780000},"page":"E9","source":"Crossref","is-referenced-by-count":9,"title":["Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th Annual Frye-Halloran Brain Tumor Symposium"],"prefix":"10.3171","volume":"34","author":[{"given":"Pamela S.","family":"Jones","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin P.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred G.","family":"Barker","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Curry","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred H.","family":"Hochberg","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Cahill","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-0340009","series-title":"Acta Neuropathol","first-page":"597","article-title":"Analysis of the IDH1 codon 132 mutation in brain tumors","volume":"116","author":"Balss","year":"2008"},{"key":"b2-0340009","series-title":"Science","first-page":"1453","article-title":"Mutations in CIC and FUBP1 contribute to human oligodendroglioma","volume":"333","author":"Bettegowda","year":"2011"},{"key":"b3-0340009","series-title":"J Clin Oncol Suppl","first-page":"abstr 2019","article-title":"IDH1 status and survival benefit from surgical resection of enhancing and nonenhancing tumor in malignant astrocytomas","volume":"30","author":"Cahill","year":"2012"},{"key":"b4-0340009","series-title":"J Natl Cancer Inst","first-page":"1473","article-title":"Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas","volume":"90","author":"Cairncross","year":"1998"},{"key":"b5-0340009","series-title":"Am J Surg Pathol","first-page":"1199","article-title":"Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes","volume":"34","author":"Capper","year":"2010"},{"key":"b6-0340009","series-title":"Brain Pathol","first-page":"245","article-title":"Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors","volume":"20","author":"Capper","year":"2010"},{"key":"b7-0340009","series-title":"J Natl Cancer Inst","first-page":"1458","article-title":"Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas","volume":"104","author":"Chou","year":"2012"},{"key":"b8-0340009","series-title":"Trends Mol Med","first-page":"387","article-title":"IDH mutations in glioma and acute myeloid leukemia","volume":"16","author":"Dang","year":"2010"},{"key":"b9-0340009","series-title":"Nature","first-page":"739","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009"},{"key":"b10-0340009","series-title":"Cancer Cell","first-page":"553","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010"},{"key":"b11-0340009","series-title":"Acta Neuropathol","first-page":"707","article-title":"Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas","volume":"120","author":"Hartmann","year":"2010"},{"key":"b12-0340009","series-title":"Acta Neuropathol","first-page":"469","article-title":"Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas","volume":"118","author":"Hartmann","year":"2009"},{"key":"b13-0340009","series-title":"Science","first-page":"425","article-title":"Altered telomeres in tumors with ATRX and DAXX mutations","volume":"333","author":"Heaphy","year":"2011"},{"key":"b14-0340009","series-title":"Oncotarget","first-page":"709","article-title":"Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas","volume":"3","author":"Jiao","year":"2012"},{"key":"b15-0340009","series-title":"J Clin Oncol","first-page":"4482","article-title":"Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin","volume":"29","author":"Lai","year":"2011"},{"key":"b16-0340009","series-title":"Acta Neuropathol","first-page":"97","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007"},{"key":"b17-0340009","series-title":"Nature","first-page":"474","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012"},{"key":"b18-0340009","series-title":"N Engl J Med","first-page":"1058","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009"},{"key":"b19-0340009","series-title":"Neurosurgery","first-page":"286","article-title":"Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas","volume":"63","author":"McGirt","year":"2008"},{"key":"b20-0340009","series-title":"Cancer Cell","first-page":"510","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr","year":"2010"},{"key":"b21-0340009","series-title":"Science","first-page":"1807","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008"},{"key":"b22-0340009","series-title":"Neurosurgery","first-page":"564","article-title":"Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias","volume":"62","author":"Stummer","year":"2008"},{"key":"b23-0340009","series-title":"Nature","first-page":"479","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012"},{"key":"b24-0340009","series-title":"Cancer Cell","first-page":"17","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011"},{"key":"b25-0340009","series-title":"N Engl J Med","first-page":"765","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009"},{"key":"b26-0340009","series-title":"J Pathol","first-page":"7","article-title":"Concurrent CIC mutations, IDH mutations, and 1p\/19q loss distinguish oligodendrogliomas from other cancers","volume":"226","author":"Yip","year":"2012"},{"key":"b1-0340009","series-title":"Acta Neuropathol","first-page":"597","article-title":"Analysis of the IDH1 codon 132 mutation in brain tumors","volume":"116","author":"Balss","year":"2008"},{"key":"b2-0340009","series-title":"Science","first-page":"1453","article-title":"Mutations in CIC and FUBP1 contribute to human oligodendroglioma","volume":"333","author":"Bettegowda","year":"2011"},{"key":"b3-0340009","series-title":"J Clin Oncol Suppl","first-page":"abstr 2019","article-title":"IDH1 status and survival benefit from surgical resection of enhancing and nonenhancing tumor in malignant astrocytomas","volume":"30","author":"Cahill","year":"2012"},{"key":"b4-0340009","series-title":"J Natl Cancer Inst","first-page":"1473","article-title":"Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas","volume":"90","author":"Cairncross","year":"1998"},{"key":"b5-0340009","series-title":"Am J Surg Pathol","first-page":"1199","article-title":"Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes","volume":"34","author":"Capper","year":"2010"},{"key":"b6-0340009","series-title":"Brain Pathol","first-page":"245","article-title":"Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors","volume":"20","author":"Capper","year":"2010"},{"key":"b7-0340009","series-title":"J Natl Cancer Inst","first-page":"1458","article-title":"Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas","volume":"104","author":"Chou","year":"2012"},{"key":"b8-0340009","series-title":"Trends Mol Med","first-page":"387","article-title":"IDH mutations in glioma and acute myeloid leukemia","volume":"16","author":"Dang","year":"2010"},{"key":"b9-0340009","series-title":"Nature","first-page":"739","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009"},{"key":"b10-0340009","series-title":"Cancer Cell","first-page":"553","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010"},{"key":"b11-0340009","series-title":"Acta Neuropathol","first-page":"707","article-title":"Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas","volume":"120","author":"Hartmann","year":"2010"},{"key":"b12-0340009","series-title":"Acta Neuropathol","first-page":"469","article-title":"Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas","volume":"118","author":"Hartmann","year":"2009"},{"key":"b13-0340009","series-title":"Science","first-page":"425","article-title":"Altered telomeres in tumors with ATRX and DAXX mutations","volume":"333","author":"Heaphy","year":"2011"},{"key":"b14-0340009","series-title":"Oncotarget","first-page":"709","article-title":"Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas","volume":"3","author":"Jiao","year":"2012"},{"key":"b15-0340009","series-title":"J Clin Oncol","first-page":"4482","article-title":"Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin","volume":"29","author":"Lai","year":"2011"},{"key":"b16-0340009","series-title":"Acta Neuropathol","first-page":"97","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007"},{"key":"b17-0340009","series-title":"Nature","first-page":"474","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012"},{"key":"b18-0340009","series-title":"N Engl J Med","first-page":"1058","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009"},{"key":"b19-0340009","series-title":"Neurosurgery","first-page":"286","article-title":"Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas","volume":"63","author":"McGirt","year":"2008"},{"key":"b20-0340009","series-title":"Cancer Cell","first-page":"510","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr","year":"2010"},{"key":"b21-0340009","series-title":"Science","first-page":"1807","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008"},{"key":"b22-0340009","series-title":"Neurosurgery","first-page":"564","article-title":"Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias","volume":"62","author":"Stummer","year":"2008"},{"key":"b23-0340009","series-title":"Nature","first-page":"479","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012"},{"key":"b24-0340009","series-title":"Cancer Cell","first-page":"17","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011"},{"key":"b25-0340009","series-title":"N Engl J Med","first-page":"765","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009"},{"key":"b26-0340009","series-title":"J Pathol","first-page":"7","article-title":"Concurrent CIC mutations, IDH mutations, and 1p\/19q loss distinguish oligodendrogliomas from other cancers","volume":"226","author":"Yip","year":"2012"}],"container-title":["Neurosurgical Focus"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/34\/2\/article-pE9.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/34\/2\/article-pE9.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/34\/2\/article-pE9.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:22:20Z","timestamp":1780734140000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/34\/2\/article-pE9.xml"}},"subtitle":["Meeting Report"],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":52,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3171\/2012.12.focus12349","relation":{},"ISSN":["1092-0684"],"issn-type":[{"value":"1092-0684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}